The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow
The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow for percutaneoustransluminal angioplasty (PTA) as well as the infusion of site-specificcontrast media for peripheral vascular anatomy (SCAN 2/15/95).The agency's most recent action allows Periflow to be marketedfor both PTA and the site-specific delivery of therapeutic pharmaceuticalsinto the peripheral vasculature. CVD, of Irvine, CA, plans tobegin U.S. shipments of Periflow by the end of this year.
In other news, Endosonics said CVD has received approval fromthe Japanese Ministry of Health to market its Controlled AngioplastyTechnology catheters in Japan.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.